pharmaceutical intermediate powder peptide lanreotide for acromegaly 108736-35-2 Supplier - Guangzhou Kafen Biotech Co.,Ltd.
Waste Management Expo 2020 MAR 12&13 BIEC, Bengaluru, India
You Are In:Home/Chemical Categories/Pharmaceutical Intermediate Powder Peptide Lanreotide For Acromegaly 108736-35-2 Suppliers/pharmaceutical intermediate powder peptide lanreotide for acromegaly 108736-35-2

pharmaceutical intermediate powder peptide lanreotide for acromegaly 108736-35-2

Description :

Welcome to inquiry!

Email: tony@kafenbio.com

WhatsApp: +8618002259573

Skype: tony_14616

www.pharmhormone.com

 
Pharmaceutical Intermediate Powder Peptide Lanreotide For Acromegaly 108736-35-2 
 
Lanreotide Basic Info.:
 
Product Name: Lanreotide
Synonyms: Lanreotide;Autogel;Bim-23014;Angiopeptin;Ipstyl 
CAS: 108736-35-2
MF: C54H69N11O10S2
MW: 1096.32
Storage temp.: −20°C
Chemical Properties: White to off-white lyophilised powder
Product Categories: hormones
 
Lanreotide Description:
 
Lanreotide (INN) is a medication used in the management of acromegaly and symptoms caused by neuroendocrine tumors, most notably carcinoid syndrome. It is a long-acting analogue of somatostatin, like octreotide. Its sequence is H-D-2Nal-Cys(1)-Tyr-D-Trp-Lys-Val-Cys(1)-Thr-NH2.
 
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas. In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma,a rare tumor of the pituitary gland which secretes TSH.
 
Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.
 
Lanreotide Indications:
 
Lanreotide is used in the treatment of acromegaly, due to both pituitary and non-pituitary growth hormone-secreting tumors, and the management of symptoms caused by neuroendocrine tumors, particularly carcinoid tumors and VIPomas.  In the United States and Canada, lanreotide is only indicated for the treatment of acromegaly. In the United Kingdom, it is also indicated in the treatment of thyrotrophic adenoma, a rare tumor of the pituitary gland which secretes.
 
Lanreotide also shows activity against non-endocrine tumors, and, along with other somatostatin analogues, is being studied as a possible general antitumor agent.
 
Lanreotide ,In Dec 2014 the US FDA approved lanreotide for the treatment of patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
 
Lanreotide Side Effects:
 
Lanreotide ,The main side effects of lanreotide treatment are mild to moderate pain at the injection site and gastrointestinal disturbances, such as diarrhea, nausea and vomiting. Isolated cases of gallstone formation have been associated with use of lanreotide, particularly over long periods of time.
 

Seller Info :

Guangzhou Kafen Biotech Co.,Ltd.

Product Details :

Brandkafen
Cas Number108736-35-2

Categories :

Hormone drugs
Pharmaceutical raw materials
Pharmaceutical intermediates
API Intermediates
About Suppliers :
Guangzhou Kafen Biotech Co.,Ltd.
Welcome to inquiry! Email: tony@kafenbio.com WhatsApp: +8618002259573 Skype: tony_14616 http://www.pharmhormone.com/ Guangzhou Kafen Biotech Co.,Ltd is a high-tech and professional company founded in 2002,which specialized in developing, manufacturing,distributing steroid hormone powders and Read More..

Buy pharmaceutical intermediate powder peptide lanreotide for acromegaly 108736-35-2 from other suppliers.View All


www.worldofchemicals.com uses cookies to ensure that we give you the best experience on our website. By using this site, you agree to our Privacy Policy and our Terms of Use. X